Century Therapeutics, Inc. (IPSC) Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Century Therapeutics, Inc. NASDAQ:IPSC Healthcare · Biotechnology
Mkt Cap $266.18M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
Century Therapeutics will attend the 2026 Jefferies Global Healthcare Conference in London on November 18, 2026.
Interested investors can arrange 1x1 meetings with management through their Jefferies representatives.
The notice contains no new clinical, financial, or corporate developments; it is a scheduling announcement only.
• 18d ago AI analysis › Press Release
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
Century Therapeutics presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the EASD 2026 annual meeting in Milan.
Data showed sustained glycemic control in diabetic mice over eleven months, consistent production across five clinical-scale batches, successful liver engraftment via the intended clinical route, and maintained function after 96 hours of cold storage.
The company reaffirmed its IND submission remains on track for Q4 2026, with initial clinical data anticipated in the second half of 2027.
• 0mo ago AI analysis › Press Release
Century Therapeutics Appoints Joseph Truitt to Board of Directors
Century Therapeutics appointed Joseph Truitt to its board of directors. Truitt currently serves as CEO of clinical-stage genome-editing company iECURE and is Chairman of the Board of Larimar Therapeutics (NASDAQ: LRMR).
Truitt previously ran BioSpecifics Technologies until its December 2020 acquisition by Endo International and spent more than a decade at Achillion Pharmaceuticals, rising to CEO before its January 2020 acquisition by Alexion. He is also a former U.S. Marine Corps captain.
The appointment comes as Century advances CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, toward an IND submission in Q4 2026 following FDA pre-IND alignment, and CNTY-308, a CD19-targeted CAR-iT therapy, toward clinical entry in 2026.
• 1mo ago AI analysis › Press Release ● Major
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics reported second quarter 2026 financial results with cash, cash equivalents, and investments of $197.2 million, extending the company's operating runway into the first quarter of 2029.
The company completed a pre-IND meeting with the FDA for CNTY-813, reaching alignment on the nonclinical data package and Phase 1/2 trial design, keeping the IND submission on track for the fourth quarter of 2026.
Operating expenses decreased compared to the prior year, with R&D expenses at $19.6 million, while CNTY-308 remains on track to enter the clinic in 2026.
• 2mo ago AI analysis › Press Release ● Critical
IHI Power Services Corp. Rebrands as Kyuden Energy Partners Following Acquisition by Japan's Kyuden Group
businesswire.com • 3mo ago Press Release
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
Century Therapeutics announced that its lead asset CNTY-813 has been selected for oral presentations at two major scientific conferences in October 2026.
The presentations at EASD and the Breakthrough T1D Congress will highlight preclinical data demonstrating scalable manufacturing and immune evasion capabilities of the iPSC-derived islet therapy.
The company reaffirmed its target to submit an Investigational New Drug (IND) application for CNTY-813 in the fourth quarter of 2026.
• 3mo ago AI analysis › Press Release
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Century Therapeutics presented new preclinical data for CNTY-813 at the ADA 2026 Scientific Sessions, showing durable glucose control for over eight months in diabetic mice.
The data confirmed that the Allo-Evasion™ 5.0 engineering allows the islet cells to evade immune rejection in humanized mouse models without the need for chronic immunosuppression.
Century has established its Phase 1 manufacturing process with consistent product quality and targets an IND submission in the fourth quarter of 2026, with initial clinical data expected in the second half of 2027.
• 4mo ago AI analysis › Press Release ● Major
Century Therapeutics Reports First Quarter Financial Results and Business Updates
globenewswire.com • 5mo ago Press Release
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
Century Therapeutics announced it will deliver an oral presentation on preclinical data for CNTY-813, its iPSC-derived islet cell therapy for type 1 diabetes, at the upcoming ADA Scientific Sessions.
The presentation will highlight the program's use of the Allo-Evasion™ 5.0 engineering technology, which aims to enable off-the-shelf therapies without chronic immunosuppression.
Management emphasized that the program is advancing through IND-enabling development with a focus on scalability and broad patient access.
• 6mo ago AI analysis › 
